JP2016501520A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501520A5
JP2016501520A5 JP2015543449A JP2015543449A JP2016501520A5 JP 2016501520 A5 JP2016501520 A5 JP 2016501520A5 JP 2015543449 A JP2015543449 A JP 2015543449A JP 2015543449 A JP2015543449 A JP 2015543449A JP 2016501520 A5 JP2016501520 A5 JP 2016501520A5
Authority
JP
Japan
Prior art keywords
substituted
alkynyl
alkenyl
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015543449A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501520A (ja
JP6463687B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/074552 external-priority patent/WO2014080004A1/en
Publication of JP2016501520A publication Critical patent/JP2016501520A/ja
Publication of JP2016501520A5 publication Critical patent/JP2016501520A5/ja
Application granted granted Critical
Publication of JP6463687B2 publication Critical patent/JP6463687B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015543449A 2012-11-26 2013-11-25 Fgfr3の発現の調節のための組成物及び方法 Expired - Fee Related JP6463687B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261729922P 2012-11-26 2012-11-26
US61/729,922 2012-11-26
PCT/EP2013/074552 WO2014080004A1 (en) 2012-11-26 2013-11-25 Compositions and methods for modulation of fgfr3 expression

Publications (3)

Publication Number Publication Date
JP2016501520A JP2016501520A (ja) 2016-01-21
JP2016501520A5 true JP2016501520A5 (enExample) 2016-12-01
JP6463687B2 JP6463687B2 (ja) 2019-02-06

Family

ID=49639882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015543449A Expired - Fee Related JP6463687B2 (ja) 2012-11-26 2013-11-25 Fgfr3の発現の調節のための組成物及び方法

Country Status (11)

Country Link
US (1) US9725723B2 (enExample)
EP (1) EP2922955B1 (enExample)
JP (1) JP6463687B2 (enExample)
KR (1) KR20150088305A (enExample)
CN (1) CN104903448B (enExample)
BR (1) BR112015012051A2 (enExample)
CA (1) CA2889993A1 (enExample)
DK (1) DK2922955T3 (enExample)
MX (1) MX2015006289A (enExample)
RU (1) RU2015120645A (enExample)
WO (1) WO2014080004A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171914A1 (en) 2008-12-02 2011-07-28 Chiralgen Ltd Method for the synthesis of phosphorus atom modified nucleic acids
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
WO2012068405A2 (en) 2010-11-17 2012-05-24 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
US9605019B2 (en) 2011-07-19 2017-03-28 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
CN112007045B (zh) 2012-07-13 2026-01-06 波涛生命科学有限公司 手性控制
CA2889993A1 (en) 2012-11-26 2014-05-30 Roche Innovation Center Copenhagen A/S Compositions and methods for modulation of fgfr3 expression
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
KR102423317B1 (ko) 2014-01-16 2022-07-22 웨이브 라이프 사이언시스 리미티드 키랄 디자인
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP4470621A3 (en) 2018-03-19 2025-05-07 Taiho Pharmaceutical Co., Ltd. Use of sodium alkyl sulfate
JP7762071B2 (ja) * 2020-01-31 2025-10-29 国立大学法人京都大学 軟骨形成異常症の治療
JPWO2022211095A1 (enExample) * 2021-03-31 2022-10-06

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US4914210A (en) 1987-10-02 1990-04-03 Cetus Corporation Oligonucleotide functionalizing reagents
US4962029A (en) 1987-10-02 1990-10-09 Cetus Corporation Covalent oligonucleotide-horseradish peroxidase conjugate
RU95114435A (ru) 1992-12-14 1997-05-20 Ханивелл Инк. (Us) Система с бесщеточным двигателем постоянного тока
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CA2303299C (en) 1997-09-12 2016-02-23 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20030087854A1 (en) * 2001-09-10 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of fibroblast growth factor receptor 3 expression
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004043979A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9045518B2 (en) 2002-11-18 2015-06-02 Santaris Pharma A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
WO2007061127A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
ES2351674T3 (es) 2006-01-27 2011-02-09 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en la posición 6.
DK2021472T3 (da) 2006-05-05 2011-09-19 Isis Pharmaceuticals Inc Forbindelser og fremgangsmåder til modulering af genekspression
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
MX2009002859A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Enlazadores biodegradables a base de ester impedido para suministro de oligonucleotidos.
MX2009002856A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Conjugados polimericos que contienen porciones cargadas positivamente.
US9398493B2 (en) 2006-10-30 2016-07-19 Nokia Technologies Oy Method, apparatus, and system providing operator controlled mobility for user equipment
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
EP2176280B2 (en) 2007-07-05 2015-06-24 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
WO2009090182A1 (en) 2008-01-14 2009-07-23 Santaris Pharma A/S C4'-substituted - dna nucleotide gapmer oligonucleotides
AT507215B1 (de) 2009-01-14 2010-03-15 Boehler Edelstahl Gmbh & Co Kg Verschleissbeständiger werkstoff
HRP20150965T1 (hr) * 2009-03-25 2015-11-06 Genentech, Inc. Anti-fgr3 protutijela i metode koje ih koriste
WO2011139842A2 (en) * 2010-04-28 2011-11-10 Marina Biotech, Inc. Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
CA2889993A1 (en) 2012-11-26 2014-05-30 Roche Innovation Center Copenhagen A/S Compositions and methods for modulation of fgfr3 expression
US9778708B1 (en) 2016-07-18 2017-10-03 Lenovo Enterprise Solutions (Singapore) Pte. Ltd. Dual sided latching retainer for computer modules

Similar Documents

Publication Publication Date Title
JP2016503300A5 (enExample)
JP2013508347A5 (enExample)
JP2012140436A5 (ja) 物質
JP2013505929A5 (enExample)
JP2015042636A5 (ja) 有機化合物
JP2017119663A5 (enExample)
JP2015181191A5 (enExample)
JP2009535462A5 (enExample)
JP2016505614A5 (enExample)
EP2658857A4 (en) SUBSTITUTED PURIN NUCLEOSIDES, PHOSPHOROAMIDATES AND PHOSPHORODIAMIDATE DERIVATIVES FOR THE TREATMENT OF VIRUS INFECTIONS
JP2013102146A5 (ja) 化合物
JP2016521119A5 (enExample)
JP2013521295A5 (enExample)
JP2014509612A5 (enExample)
JP2010254680A5 (ja) 複素環化合物、及び発光素子
JP2014526533A5 (enExample)
JP2012528196A5 (enExample)
JP2010254679A5 (ja) トリアゾール誘導体、発光素子、及び発光装置
JP2011016798A5 (enExample)
JP2014508179A5 (enExample)
JP2018531301A5 (enExample)
JP2011079866A5 (enExample)
JP2015083560A5 (ja) 有機金属錯体
JP2014101364A5 (enExample)
JP2015044793A5 (ja) 有機化合物